Genentech Inc. is pushing a “value-based” approach to pricing combination therapy that would allow for reduced list prices for its Tecentriq (atezolizumab) and Avastin (bevacizumab) when used in combination for lung cancer patients.
The company has been in discussions with HHS, FDA and the Centers for Medicare and Medicaid Services to advance the policy, which it calls the